Protara Therapeutics Inc
TARA5.410USD
+0.140+2.66%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
208.76MMarket Cap
LossP/E TTM
More Details of Protara Therapeutics Inc Company
Protara Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in advancing transformative therapies for people with cancer and rare diseases. The Company’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase II trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naive to treatment with Bacillus Calmette-Guerin (BCG), as well as a Phase II trial in pediatric patients with LMs. In addition, the Company is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes.
Protara Therapeutics Inc Info
Ticker SymbolTARA
Company nameProtara Therapeutics Inc
IPO dateOct 22, 2014
CEOShefferman (Jesse)
Number of employees28
Security typeOrdinary Share
Fiscal year-endOct 22
Address345 Park Avenue South
CityNEW YORK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code10010
Phone16468440337
Websitehttps://protaratx.com/
Ticker SymbolTARA
IPO dateOct 22, 2014
CEOShefferman (Jesse)
Company Executives of Protara Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Luke M. Beshar, CPA
Mr. Luke M. Beshar, CPA
Independent Chairman of the Board
Independent Chairman of the Board
198.00K
--
Dr. Jacqueline Zummo, Ph.D.
Dr. Jacqueline Zummo, Ph.D.
Chief Scientific Operations Officer
Chief Scientific Operations Officer
52.40K
-9.50%
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
51.00K
+64.52%
Mr. William (Bill) Conkling
Mr. William (Bill) Conkling
Chief Commercial Officer
Chief Commercial Officer
50.00K
--
Ms. Hannah Fry
Ms. Hannah Fry
Controller
Controller
36.81K
+23.38%
Dr. Roger J. Garceau, M.D.
Dr. Roger J. Garceau, M.D.
Independent Director
Independent Director
33.00K
--
Mr. Gregory P. Sargen
Mr. Gregory P. Sargen
Independent Director
Independent Director
31.00K
--
Dr. Michael Edward (Mike) Solomon, Ph.D.
Dr. Michael Edward (Mike) Solomon, Ph.D.
Independent Director
Independent Director
26.50K
--
Mr. Patrick (Pat) Fabbio
Mr. Patrick (Pat) Fabbio
Chief Financial Officer
Chief Financial Officer
4.27K
-79.09%
Ms. Justine O'Malley
Ms. Justine O'Malley
Investor Relations
Investor Relations
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Luke M. Beshar, CPA
Mr. Luke M. Beshar, CPA
Independent Chairman of the Board
Independent Chairman of the Board
198.00K
--
Dr. Jacqueline Zummo, Ph.D.
Dr. Jacqueline Zummo, Ph.D.
Chief Scientific Operations Officer
Chief Scientific Operations Officer
52.40K
-9.50%
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
51.00K
+64.52%
Mr. William (Bill) Conkling
Mr. William (Bill) Conkling
Chief Commercial Officer
Chief Commercial Officer
50.00K
--
Ms. Hannah Fry
Ms. Hannah Fry
Controller
Controller
36.81K
+23.38%
Dr. Roger J. Garceau, M.D.
Dr. Roger J. Garceau, M.D.
Independent Director
Independent Director
33.00K
--
Revenue Breakdown
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Janus Henderson Investors
8.20%
Velan Capital Investment Management LP
4.14%
BlackRock Institutional Trust Company, N.A.
3.96%
Blackstone Alternative Asset Management, L.P.
3.70%
The Vanguard Group, Inc.
3.69%
Other
76.31%
Shareholders
Shareholders
Proportion
Janus Henderson Investors
8.20%
Velan Capital Investment Management LP
4.14%
BlackRock Institutional Trust Company, N.A.
3.96%
Blackstone Alternative Asset Management, L.P.
3.70%
The Vanguard Group, Inc.
3.69%
Other
76.31%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
21.51%
Investment Advisor
16.18%
Hedge Fund
7.28%
Venture Capital
4.46%
Individual Investor
2.11%
Research Firm
1.32%
Bank and Trust
0.15%
Pension Fund
0.04%
Other
46.95%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
133
30.21M
78.29%
-4.37M
2025Q2
113
30.48M
79.01%
-5.04M
2025Q1
109
30.14M
79.11%
-5.49M
2024Q4
103
31.00M
91.11%
+17.03M
2024Q3
78
11.90M
57.00%
-1.22M
2024Q2
78
11.87M
56.87%
+435.17K
2024Q1
73
5.94M
51.57%
-1.39M
2023Q4
74
5.63M
49.24%
-1.76M
2023Q3
82
6.95M
61.22%
-1.14M
2023Q2
92
7.24M
64.00%
-2.26M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Janus Henderson Investors
4.10M
10.63%
+314.44K
+8.30%
Jun 30, 2025
Velan Capital Investment Management LP
2.14M
5.54%
+471.20K
+28.25%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
1.96M
5.09%
+1.34M
+213.59%
Jun 30, 2025
Blackstone Alternative Asset Management, L.P.
1.91M
4.95%
+165.62K
+9.50%
Jun 30, 2025
The Vanguard Group, Inc.
1.80M
4.67%
+199.13K
+12.42%
Jun 30, 2025
Acorn Capital Advisors, LLC
1.75M
4.54%
+472.31K
+36.91%
Jun 30, 2025
Catalio Capital Management, LP
1.63M
4.22%
+537.68K
+49.39%
Jun 30, 2025
Integral Health Asset Management, LLC
1.40M
3.63%
--
--
Jun 30, 2025
UBS Financial Services, Inc.
1.13M
2.94%
+497.45K
+78.13%
Jun 30, 2025
5AM Ventures
800.00K
2.07%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.03%
Avantis US Small Cap Equity ETF
0.02%
Invesco Russell 2000 Dynamic Multifactor ETF
0.02%
iShares Russell 2000 Value ETF
0.02%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
Global X Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
DFA Dimensional US Sustainability Core 1 ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.03%
Avantis US Small Cap Equity ETF
Proportion0.02%
Invesco Russell 2000 Dynamic Multifactor ETF
Proportion0.02%
iShares Russell 2000 Value ETF
Proportion0.02%
ProShares UltraPro Russell2000
Proportion0.01%
iShares Russell 2000 ETF
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Protara Therapeutics Inc?
The top five shareholders of Protara Therapeutics Inc are:
Janus Henderson Investors holds 4.10M shares, accounting for 10.63% of the total shares.
Velan Capital Investment Management LP holds 2.14M shares, accounting for 5.54% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 1.96M shares, accounting for 5.09% of the total shares.
Blackstone Alternative Asset Management, L.P. holds 1.91M shares, accounting for 4.95% of the total shares.
The Vanguard Group, Inc. holds 1.80M shares, accounting for 4.67% of the total shares.
Janus Henderson Investors holds 4.10M shares, accounting for 10.63% of the total shares.
Velan Capital Investment Management LP holds 2.14M shares, accounting for 5.54% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 1.96M shares, accounting for 5.09% of the total shares.
Blackstone Alternative Asset Management, L.P. holds 1.91M shares, accounting for 4.95% of the total shares.
The Vanguard Group, Inc. holds 1.80M shares, accounting for 4.67% of the total shares.
What are the top three shareholder types of Protara Therapeutics Inc?
The top three shareholder types of Protara Therapeutics Inc are:
Janus Henderson Investors
Velan Capital Investment Management LP
BlackRock Institutional Trust Company, N.A.
Janus Henderson Investors
Velan Capital Investment Management LP
BlackRock Institutional Trust Company, N.A.
How many institutions hold shares of Protara Therapeutics Inc (TARA)?
As of 2025Q3, 133 institutions hold shares of Protara Therapeutics Inc, with a combined market value of approximately 30.21M, accounting for 78.29% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -0.72%.
What is the biggest source of revenue for Protara Therapeutics Inc?
In FY2019, the -- business generated the highest revenue for Protara Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
